OakChart

Tempest Therapeutics Inc

TPSTHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 9:51 AM ET

0.4182+0.0440 (11.76%)
2026-11-11 15:52 CET
Market cap
7.48 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-40.47 USD m
Free cash flow, TTM
-20.73 USD m
EPS diluted, TTM
-4.48
P/E
-
Compare

Price

TPST against its 20, 50 and 200-day averages
2050200missearnings
2.004.0052.3M104.6MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26TPSTclose 0.4220-day 0.4950-day 0.71200-day 1.410.42

96.2% under 10.93 on 30 Oct 2025. Last 15 sessions, 66.2% high to low

Profile

TPST
52-week range, 1% of the way up
0.349.75

Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.

Employees4
IPONov 12, 2012
Beta-1.51
ATR, 14d0.06
Rel volume2.20
Short float2.00%
Insider own39.64%
Inst own5.26%

Snapshot

6 groups

Valuation

Index-
Market Cap8.36M
Enterprise Value15.14M
Income-40.47M
Sales0.00M
Book/sh-0.07
Cash/sh0.04
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees4
IPONov 12, 2012

Ratios

P/E-
Forward P/E-
PEG-
P/S-
P/B-
P/C10.72
P/FCF-
EV/EBITDA-
EV/Sales-
Quick Ratio0.38
Current Ratio0.38
Debt/Eq-
LT Debt/Eq-
Option/ShortNo / Yes

Earnings

EPS (ttm)-4.48
EPS next Y-0.90
EPS next Q-0.32
EPS this Y54.98%
EPS next Y68.42%
EPS next 5Y-
EPS past 3/5Y46.00% 76.03%
Sales past 3/5Y- -
EPS Y/Y TTM69.34%
Sales Y/Y TTM-
EPS Q/Q83.35%
Sales Q/Q-
EarningsAug 13 AMC
EPS/Sales Surpr.- -

Ownership

Insider Own39.64%
Insider Trans3.01%
Inst Own5.26%
Inst Trans14.17%
ROA-237.25%
ROE-931.14%
ROIC-780.86%
Gross Margin-
Oper. Margin-
Profit Margin-
SMA20-15.52%
SMA50-41.32%
SMA200-70.31%
Trades-

Technical

Shs Outstand15.98M
Shs Float12.07M
Short Float2.00%
Short Ratio0.09
Short Interest0.24M
52W High9.75 -95.71%
52W Low0.34 24.21%
Volatility15.86% 9.93%
ATR (14)0.06
RSI (14)32.57
Beta-1.51
Rel Volume2.20
Avg Volume2.55M
Volume566,716

Performance

Perf Week-9.73%
Perf Month-38.62%
Perf Quarter-64.26%
Perf Half Y-77.27%
Perf YTD-85.43%
Perf Year-95.65%
Perf 3Y-99.00%
Perf 5Y-99.72%
Perf 10Y-100.00%
Recom1.00
Target Price7.00
Prev Close0.37
Price0.42
Change %11.76%

Analyst ratings

latest 5 of 5
DateActionAnalystRating changeTargetImplied
Jan 22, 2026UpgradeHH.C. WainwrightNeutral → Buy$11+2,530.3%
Apr 10, 2025DowngradeBScotiabankSector Outperform → Sector Perform
Apr 10, 2025DowngradeHH.C. WainwrightBuy → Neutral
Mar 14, 2024InitiatedBScotiabankSector Outperform$13+3,008.6%
Feb 08, 2024InitiatedJJefferiesBuy$15+3,486.8%

Peers

Mkt cap
TickerCompanyMkt cap
TVRDTvardi Therapeutics Inc20.14M
ACTUActuate Therapeutics Inc17.35M
CRDFCardiff Oncology Inc60.69M
IMRXImmuneering Corp251.93M
BDTXBlack Diamond Therapeutics Inc93.36M
HOWLWerewolf Therapeutics Inc47.62M
KZIAKazia Therapeutics Limited ADR87.55M
OSTXOS Therapies Inc46.72M
ZNTLZentalis Pharmaceuticals Inc186.63M
PRLDPrelude Therapeutics Inc302.85M

Insider trading

2 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Angel MatthewCEO and PresidentMar 24 '26Buy2.16231,482500,001231,482Jun 23 04:56 PM
Angel MatthewCEO and PresidentMar 24 '26Buy2.16231,482500,001231,482Mar 25 05:32 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B

News

latest 14 of 103
  • Tempest Therapeutics Exercises Option to License Senlang's CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate (GlobeNewswire) +11.76%
  • Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise (GlobeNewswire) -6.77%
  • Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors (GlobeNewswire) -7.80%
  • Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform (GlobeNewswire) +60.18%
  • Tempest Therapeutics Announces Up to $7.5 Million Private Placement (GlobeNewswire)
  • Loading…
  • Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
  • Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -13.25%
  • Tempest Announces Development Collaboration with Senlang Biotechnology for TPST-4003, a CD7-Targeted Next-Generation In Vivo CAR-T (GlobeNewswire)
  • Tempest Unveils Next-Generation In Vivo CAR-T Pipeline, with First Clinical Study Planned for the Fourth Quarter of 2026 (GlobeNewswire) +9.13%
  • Tempest Therapeutics Appoints Drake Richey and John Yee, MD, MPH to Board of Directors (GlobeNewswire)
  • Tempest Therapeutics Announces Warrant Exercise for Approximately $2 Million in Gross Proceeds (GlobeNewswire) -11.56%
  • Tempest Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +13.59% -12.44%
  • Tempest Presents Clinical Update at ISCT 2026 Annual Meeting (GlobeNewswire) -6.05%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-13-0.340--0.3400.00--
2026Q12026-05-14-2.530-0.280-2.5340.000.001
2025Q42026-03-30-0.310-0.620-0.8160.000.001
2025Q32025-11-05-0.790--0.7910.00--
2025Q22025-08-11-2.070-3.230-2.0690.000.001
2025Q12025-05-13-3.160-3.293-3.1590.000.003
2024Q42025-03-27-4.030-3.274-4.0840.000.005
2024Q32024-11-12-5.330-4.706-5.3180.000.005
2024Q22024-08-08-5.460-5.242-5.5180.000.005
2024Q12024-05-09-4.680-5.234-4.6210.000.006
2023Q42024-03-19-4.940-5.034-4.5230.000.006
2023Q32023-11-08-6.240-7.450-6.2470.000.004
2023Q22023-08-10-7.020-6.728-6.9890.000.004
2023Q12023-05-10-7.150-8.353-7.2130.000.004
2022Q42023-03-22-7.280-9.884-11.2510.000.004
2022Q32022-11-08-8.580-10.433-8.5300.000.004

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2018FY-3,428-442.65-3,4270.000.00
2019FY-633.75-621.51-634.050.000.00
2020FY-376.35-368.55-8,001--
2021FY-97.110-83.373-97.0700.000.00
2022FY-40.170-42.275-40.1960.000.00
2023FY-24.830-25.146-24.8690.000.00
2024FY-19.500-17.495-19.4960.000.00
2025FY-6.330-6.100-6.3300.000.00
2026FY--2.850--0.00
2027FY--0.900--0.00
2028FY--0.890--4.30
2029FY--4.230--0.00

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-09-231000.000.000.00
2026Q3S2026-05-151000.000.000.00
2026Q3S2026-03-301000.000.000.00
2026Q3R2026-10-20100-0.32-0.32-0.32
2026Q3R2026-09-23110-0.32-0.32-0.32
2026Q3R2026-05-15100-0.35-0.35-0.35
2026Q3R2026-03-30100-0.35-0.35-0.35
2026Q3E2026-10-20100-0.32-0.32-0.32
2026Q3E2026-09-23110-0.32-0.32-0.32
2026Q3E2026-05-15100-0.35-0.35-0.35
2026Q3E2026-03-30100-0.35-0.35-0.35
2026Q2S2026-05-151000.000.000.00
2026Q2S2026-05-141000.000.000.00
2026Q2S2026-03-301000.000.000.00

Estimate history

EPS, annual-941283.245-3427.451-634.05-8000.581-97.07-40.196-24.869-19.496-6.329-4.4849
Period201720182019202020212022202320242025TTM
EPS, quarterly-5.518-5.318-4.084-3.159-2.069-0.791-0.816-2.534-0.345
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual0000000000
Period201720182019202020212022202320242025TTM
Sales, quarterly000000000
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual00.0690.0940.0030.5320.8091.6963.3824.92715.979
Period201720182019202020212022202320242025MRQ
Shares, quarterly1.8832.0443.3823.524.4384.444.92714.34415.979
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue0.000.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.250.270.390.381.811.270.811.050.03
Gross Profit-0.25-0.27-0.39-0.38-1.81-1.27-0.81-1.05-0.03
Selling, General and Administrative Excl. Other18.2126.3141.6428.7832.8325.7218.4844.3523.08
Research and Development2.8712.3928.1217.5022.5317.1714.3927.8414.43
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-18.46-26.57-42.03-29.16-34.64-26.99-19.30-45.40-23.12
Interest Expense-0.211.321.451.621.320.00-0.13
Unusual Expense22.180.000.000.000.000.000.00-3.72
Net Income Before Taxes-40.47-26.26-41.84-29.49-35.71-28.30-19.21-44.57-27.18
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-40.47-26.26-41.84-29.49-35.71-28.30-19.21-44.57-27.18
Net Income From Continuing Operations-40.47-26.26-41.84-29.49-35.71-28.30-19.21-44.57-27.19
Net Income-40.47-26.26-41.84-29.49-35.71-28.30-19.21-44.57-27.19
EPS (Recurring)-1.64-6.33-19.50-24.87-40.20-97.07-8,000.58-634.05-3,099.40
EPS (Basic, Before Extraordinaries)-4.48-6.33-19.50-24.87-40.20-97.07-8,000.58-634.05-3,427.45
EPS (Diluted)-4.48-6.33-19.50-24.87-40.20-97.07-8,000.58-634.05-3,427.45
EBITDA-18.21-26.31-41.64-28.78-32.83-25.72-18.48-44.35-23.08
Non-Operating Income (Expense)0.170.521.501.110.550.000.090.83-0.21
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.753.125.302.551.561.100.454.321.43
Shares Outstanding15.984.933.381.700.810.530.000.090.07
Market Capitalization7.487.4836.6963.0212.0936.4940.66123.1218.99

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue0.000.000.000.000.000.000.000.00
Cost of Goods Sold Incl. D&A0.060.060.070.070.070.070.050.10
Gross Profit-0.06-0.06-0.07-0.07-0.07-0.07-0.05-0.10
Selling, General and Administrative Excl. Other5.195.484.013.537.9010.8713.8710.45
Research and Development1.780.070.490.533.827.5710.697.47
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-5.25-5.54-4.08-3.60-7.97-10.94-13.92-10.55
Interest Expense0.000.00--0.050.160.250.33
Unusual Expense0.0022.180.000.000.000.000.000.00
Net Income Before Taxes-5.24-27.70-4.02-3.51-7.87-10.86-13.81-10.56
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-5.24-27.70-4.02-3.51-7.87-10.86-13.81-10.56
Net Income From Continuing Operations-5.24-27.70-4.02-3.51-7.87-10.86-13.81-10.56
Net Income-5.24-27.70-4.02-3.51-7.87-10.86-13.81-10.56
EPS (Recurring)-0.34-1.11-0.82-0.79-2.07-3.16-4.08-5.32
EPS (Basic, Before Extraordinaries)-0.34-2.53-0.82-0.79-2.07-3.16-4.08-5.32
EPS (Diluted)-0.34-2.53-0.82-0.79-2.07-3.16-4.08-5.32
EBITDA-5.19-5.48-4.01-3.53-7.90-10.87-13.87-10.45
Non-Operating Income (Expense)0.010.020.060.090.140.240.350.32
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense-0.120.230.580.061.091.391.331.33
Shares Outstanding15.9814.344.934.444.443.523.382.04
Market Capitalization7.4822.1114.1445.6427.7933.7736.6937.19

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments7.7130.2739.2331.2351.8318.8263.5177.7217.62
Short Term Receivables0.000.000.000.000.000.261.282.331.03
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets0.561.211.131.7217.130.746.343.371.08
Total Current Assets8.2731.4740.3632.9568.9619.8271.1383.4219.74
Net Property, Plant & Equipment8.149.5310.7912.714.162.993.330.000.00
Total Investments and Advances0.390.390.390.000.000.000.000.440.00
Intangible Assets--------0.00
Deferred Tax Assets2.202.54-------
Other Assets0.130.100.060.430.110.050.510.210.07
Total Assets19.1344.0251.6046.0973.2422.8674.9784.0719.81
Short Term Debt Incl. Current Port. of LT Debt1.197.225.241.411.440.791.960.190.17
Accounts Payable1.042.450.841.110.991.071.502.001.30
Other Current Liabilities1.084.553.334.7617.591.369.077.632.62
Total Current Liabilities3.3114.229.417.2820.033.2212.529.824.09
Long Term Debt6.958.1415.4220.7017.091.732.560.380.60
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Deferred Tax Liabilities2.202.54-------
Other Liabilities0.000.000.000.000.000.000.020.750.14
Total Liabilities12.4624.9024.8427.9837.124.9515.1010.954.83
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.0086.710.000.00132.92
Common Equity6.6719.1326.7718.1136.12-68.7958.5570.95-130.69
Total Shareholders Equity6.6719.1326.7718.1136.1217.9158.5570.952.23
Accumulated Minority Interest0.000.000.000.000.000.001.322.1712.76
Total Equity6.6719.1326.7718.1136.1217.9159.8773.1214.98
Total Liabilities & Stockholders Equity19.1344.0251.6046.0973.2422.8674.9784.0719.81
Book Value Per Share1.355.6515.7822.3867.94-25,441.92625.001,035.74-538,127.39
Tangible Book Value Per Share1.355.6515.7822.3867.94-25,441.92625.001,035.74-538,127.39
Full-Time Employees42517191713383436
Price to Book Ratio-5.491.92-52.960.451.011.232.100.420.69
Return on Assets-83.17-87.51-60.38-59.85-48.53-39.27-56.04-34.66-118.83
Return on Equity-203.63-182.35-131.42-131.70-81.83-50.24-68.83-40.21-153.16
Return on Invested Capital-192.86-153.45-69.90-92.01-53.19-97.80-72.93-38.12-2,991.79
Quick Ratio2.502.214.294.533.446.155.688.504.82
Current Ratio2.502.214.294.533.446.155.688.504.82

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-40.47-26.26-41.84-29.49-35.71-28.30-19.21-44.57-27.18
Depreciation0.250.270.390.381.811.270.811.050.03
Other Funds (Non Cash)23.554.316.814.431.961.690.454.352.46
Funds from Operations-16.67-21.69-34.64-24.68-31.94-25.34-17.95-39.17-24.68
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-4.06-5.131.61-2.680.87-0.61-1.07-2.051.04
Cash from Operating Activities-20.73-26.82-33.03-27.36-31.07-25.96-19.02-41.22-23.65
Capital Expenditures0.000.00-0.43-0.17-0.56-0.14-0.05-0.40-0.04
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-1.33
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.00-
Purchase or Sale of Investments0.000.000.000.000.000.000.004.382.49
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.004.382.49
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.040.040.000.00
Cash from Investing Activities0.000.00-0.43-0.17-0.56-0.10-0.013.991.12
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock7.2310.6928.9035.6016.1433.5334.6027.1438.76
Repurchase of Common Pref Stock0.000.000.000.000.000.00-0.000.000.00
Sale of Common Pref Stock7.2310.6928.9035.6016.1433.5334.6027.1438.76
Proceedsfrom Stock Options2.676.0928.5935.6016.1433.4234.5326.6738.76
Issuance or Reduction of Debt, Net0.00-6.43-4.400.00-4.7414.900.00-0.206.48
Change in Long Term Debt0.00-6.43-4.400.00-4.7414.900.00-0.206.48
Issuance of Long Term Debt0.000.000.000.000.0014.900.000.006.65
Reduction of Long Term Debt0.00-6.43-4.400.00-4.740.000.00-0.20-0.17
Net Financing Active Other Cash Flow0.000.000.000.000.0010.620.000.0033.32
Other Financing Activities Uses0.000.000.000.000.00-6.420.000.000.00
Cash from Financing Activities7.234.2624.5035.6011.4059.0634.6026.9478.55
Exchange Rate Effect------0.220.030.12
Net Change in Cash-13.50-22.56-8.968.07-20.2333.0115.58-10.2656.15
Free Cash Flow-20.73-26.82-33.46-27.53-31.63-26.09-19.07-41.62-23.68
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments0.781.807.717.5114.2821.51
Short Term Receivables0.000.000.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets0.920.640.560.590.820.92
Total Current Assets1.702.458.278.1015.1022.43
Net Property, Plant & Equipment7.437.798.148.518.859.19
Total Investments and Advances0.390.390.390.390.390.39
Deferred Tax Assets--2.20---
Other Assets0.110.120.130.130.140.15
Total Assets9.6310.7519.1317.1324.4832.16
Short Term Debt Incl. Current Port. of LT Debt1.291.241.191.151.105.25
Accounts Payable2.000.581.040.924.722.19
Other Current Liabilities1.171.491.081.461.325.74
Total Current Liabilities4.453.313.313.527.1413.18
Long Term Debt6.276.626.957.267.567.85
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities--2.20---
Other Liabilities0.000.000.000.000.000.00
Total Liabilities10.729.9312.4610.7814.7021.03
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-1.090.826.676.359.7811.13
Total Shareholders Equity-1.090.826.676.359.7811.13
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-1.090.826.676.359.7811.13
Total Liabilities & Stockholders Equity9.6310.7519.1317.1324.4832.16
Book Value Per Share-0.070.061.351.432.203.16
Tangible Book Value Per Share-0.070.061.351.432.203.16
Full-Time Employees--4---
Price to Book Ratio-5.491.212.014.662.153.03
Return on Assets-237.25-200.87-83.17-141.49-129.32-117.06
Return on Equity-931.14-721.00-203.63-405.03-322.57-282.07
Return on Invested Capital-101.18-372.41-29.53-25.81-45.38-57.20
Quick Ratio0.380.742.502.302.111.70
Current Ratio0.380.742.502.302.111.70

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-5.24-27.70-4.02-3.51-7.87-10.86
Depreciation0.060.060.070.070.070.07
Other Funds (Non Cash)1.8920.450.870.341.401.69
Funds from Operations-3.29-7.19-3.09-3.10-6.40-9.10
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.51-0.41-0.49-3.67-2.031.06
Cash from Operating Activities-2.78-7.60-3.57-6.78-8.43-8.04
Capital Expenditures0.000.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities0.000.000.000.000.000.00
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock1.751.703.770.015.431.48
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock1.751.703.770.015.431.48
Proceedsfrom Stock Options1.751.70-0.780.005.431.44
Issuance or Reduction of Debt, Net0.000.000.000.00-4.23-2.20
Change in Long Term Debt0.000.000.000.00-4.23-2.20
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.00-4.23-2.20
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.751.703.770.011.20-0.72
Net Change in Cash-1.03-5.900.19-6.77-7.23-8.76
Free Cash Flow-2.78-7.60-3.57-6.78-8.43-8.04

Revenue breakdown

Revenue split-

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.00%0.2M12.1M2.54M
2026-10-153.07%0.3M10.2M2.55M
2026-09-305.97%0.6M10.2M2.55M
2026-09-153.63%0.4M9.7M650.22K
2026-08-313.95%0.4M9.7M206.72K
2026-08-143.87%0.4M9.7M195.49K
2026-07-312.78%0.3M9.6M157.18K
2026-07-153.31%0.3M9.6M165.81K
2026-06-302.97%0.3M9.6M195.19K
2026-06-152.45%0.2M8.4M204.53K
2026-05-294.07%0.3M8.4M201.39K
2026-05-154.78%0.4M8.4M202.68K
2026-04-304.86%0.4M8.1M212.53K
2026-04-157.88%0.6M8.1M188.61K
2026-03-315.06%0.4M8.9M144.45K
2026-03-131.59%0.1M8.3M104.36K
2026-02-272.04%0.2M8.3M114.90K
2026-02-132.31%0.2M8.3M155.23K
2026-01-303.13%0.1M4.6M129.30K
2026-01-153.27%0.2M4.6M117.77K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-KCurrent report2026-11-09SEC
2026-11-068-KCurrent report2026-11-04SEC
2026-11-033Initial statement of beneficial ownership of securities2026-10-26SEC
2026-11-024Statement of changes in beneficial ownership of securities2026-10-13SEC
2026-11-023Initial statement of beneficial ownership of securities2026-10-13SEC
2026-11-02ARSAnnual report to security holders. 2025-12-31SEC
2026-10-308-KCurrent report2026-10-26SEC
2026-10-26DEF 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-09SEC
2026-10-20DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-10-208-KCurrent report2026-10-14SEC
2026-10-198-KCurrent report2026-10-13SEC
2026-10-16PRE 14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 19342026-11-09SEC
2026-10-14DNotice of sales of securities on Form D (Regulation D)SEC
2026-10-024Statement of changes in beneficial ownership of securities2026-09-22SEC
2026-10-023Initial statement of beneficial ownership of securities2026-09-22SEC
2026-10-02424B3SEC
2026-10-01EFFECTEffectiveness filing by commission orderSEC
2026-09-288-KCurrent report2026-09-22SEC
2026-09-25S-3Registration statement for specified transactions by certain issuers including face-amount certificate companiesSEC
2026-09-178-KCurrent report2026-09-14SEC
2026-09-16DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-09-168-KCurrent report2026-09-15SEC
2026-09-158-KCurrent report2026-09-11SEC
2026-09-01424B3SEC
2026-08-27CORRESPSEC
2026-08-27UPLOADUpload SubmissionSEC
2026-08-248-KCurrent report2026-08-18SEC
2026-08-21S-1General form of registration statement for all companies including face-amount certificate companiesSEC
2026-08-18DEFA14AProxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934SEC
2026-08-188-KCurrent report2026-08-17SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-031.00M200
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
SABBY MANAGEMENT, LLC3.45%
Versant Venture Management, LLC1.82%
VANGUARD CAPITAL MANAGEMENT LLC1.58%
VANGUARD FIDUCIARY TRUST CO0.47%
GEODE CAPITAL MANAGEMENT, LLC0.44%
BlackRock, Inc.0.26%
Squarepoint Ops LLC0.21%
UBS Group AG0.15%
NORTHERN TRUST CORP0.14%
CITADEL ADVISORS LLC0.13%

Funds

Fund% owned
VANGUARD TOTAL STOCK MARKET INDEX FUND0.71%
Fidelity Extended Market Index Fund0.30%
VANGUARD EXTENDED MARKET INDEX FUND0.24%
Fidelity Total Market Index Fund0.05%
Dimensional US Core Equity 1 ETF0.03%
Fidelity Series Total Market Index Fund0.03%
Dimensional U.S. Core Equity 2 ETF0.00%

OakChart. TPST. Cached 15 minutes.